Evidence map›Paper›PMID 22610049›Full record

ArticleBehavioural brain research2012

Cycloheximide impairs and enhances memory depending on dose and footshock intensity.

Paul E Gold, Sean M Wrenn

Open access · greenAbstract read
In one paragraph

Article in Behavioural brain research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. mGluR5 in amygdala modulates fear memory generalization.Frontiers in behavioral neuroscience · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Paul E GoldDepartment of Biology, Life Sciences Complex, Syracuse University, Syracuse, NY 13244, USA. pegold@syr.edu
Sean M Wrenn
Rush University Medical Center · USSyracuse University · US

Funding

AGING AND MEMORYR01AG007648 · NIA · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GOLD, PAUL E. · 1990 to 2008
$1.5M
Protein synthesis inhibitor effects on neurotransmitters and memoryR21DA024129 · NIDA · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI GOLD, PAUL E. · 2007 to 2008
$304k
NIA NIH HHS R01 AG007648NIA NIH HHS R01 AG07648NIDA NIH HHS R21 DA024129
6 · The paper itself

Abstract

This experiment examined the effects on memory of interactions of cycloheximide dose and training foot shock intensity. Mice received injections of cycloheximide (120 mg/kg, s.c.) or saline 30 min prior to inhibitory avoidance training with shock intensities of 100, 150, 250 or 300 μA (1 s duration). Memory was tested 48 h later. The saline control mice showed increasing memory latencies as a function of shock intensity. The ability of cycloheximide to impair memory increased as the training shock intensity increased. In a second experiment, mice were trained with a 200 μA (1 s duration) shock and received injections of saline or cycloheximide at one of several doses (30, 60 or 120 mg/kg). Under these training conditions, cycloheximide enhanced memory in an inverted-U dose-response manner. These findings are consistent with prior findings suggesting that protein synthesis inhibitors act on memory by altering modulators of memory formation as a secondary consequence of the inhibition of protein synthesis rather than by interfering with training-initiated synthesis of proteins required for memory formation.

Indexed as

AnimalsAvoidance LearningBiophysicsCycloheximideDisease Models, AnimalElectroshockMaleMemory DisordersMiceMice, Inbred ICRProtein Synthesis InhibitorsReaction TimeCycloheximideProtein Synthesis Inhibitors

Identifiers

PMID22610049
PMCPMC3402692
OpenAlexW2053674179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.